Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.92%
#2 Palladium Network Palladium Network +8.47%
#3 Cryptopia Cryptopia +4.23%
#4 Victoria VR Victoria VR +4.09%
#5 Lisk Lisk +3.02%
#6 Test Test +2.89%
#7 GRVT Token GRVT Token +2.39%
#8 Biconomy Biconomy +2.25%
#9 COTI COTI +2.22%
#10 Bless Bless +2.18%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Arch Therapeutics, Inc. Arch Therapeutics, Inc.

Arch Therapeutics, Inc.

ARTH
Rangering i aksjer #42478
Arch Therapeutics, Inc., operating alongside its affiliated companies,... Arch Therapeutics, Inc., operating alongside its affiliated companies, functions as a biotechnology firm within the United States. The organization focuses on developing and commercializing products derived from its unique AC5 self-assembling technology platform. These innovations are engineered to arrest bleeding, control fluid leakage, and assist in wound care during surgical interventions, following trauma, throughout interventional medical procedures, or in cases of disease. Its leading products, the AC5 advanced wound system and the AC5 topical hemostat, are specifically designed for application on the skin, proving effective for managing intricate chronic wounds or acute surgical injuries. The company was established in 2006 and is headquartered in Framingham, Massachusetts.
Aksjekurs
$0.0009
Sist synkronisert: 2025-05-27
Markedsverdi
$1.15K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Arch Therapeutics, Inc. (ARTH)

Kategori

Healthcare
P/E-forhold for Arch Therapeutics, Inc. (ARTH)
P/E-forhold per August 2026 TTM: 0.00
Ifølge Arch Therapeutics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0.00. Ved slutten av 2022 hadde selskapet en P/E på -1.08.
P/E-forholdshistorikk for Arch Therapeutics, Inc. fra 2011 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) 0.00 -100.00%
2023 -0.57 -46.88%
2022 -1.08 -75.26%
2021 -4.35 -99.73%
2020 -1.62K -44.60%
2019 -2.93K 15.52%
2018 -2.54K -14.51%
2017 -2.97K 7.68%
2016 -2.76K 88.35%
2015 -1.46K 390.49%
2014 -298.39 -75.27%
2013 -1.21K -57.39%
2012 -2.83K -93.43%
2011 -43.07K 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.